Items Tagged ‘hormone refractory’

June 7th, 2017

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

By

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months to 33 months according to the results of a clinical study featured at the 2017 American […]

View full entry

Tags: abiraterone, hormone refractory, metastatic prostate cancer, News, Prostate Cancer, zytiga


September 15th, 2014

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer

By

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine.  Xtandi originally gained U.S. approval in 2012 for use in patients with castration-resistant prostate cancer that has spread beyond the prostate only after they had […]

View full entry

Tags: enazlutamide, hormone refractory, metastatic prostate cancer, Metastatic Stage IV (D) Prostate Cancer, News, PREVAIL trial, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi


September 3rd, 2014

Cabozantinib Development in Prostate Cancer Halted

By

Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been halted due to discouraging results in a pivotal clinical trial.  Enrollment in a second, phase III study of cabozantinib in prostate cancer has also been halted based on the negative outcome from the first study. Prostate […]

View full entry

Tags: cabozantinib, hormone refractory, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer